Charles Schwab Investment Management Inc. Cuts Stake in Definitive Healthcare Corp. (NASDAQ:DH)

Charles Schwab Investment Management Inc. cut its holdings in Definitive Healthcare Corp. (NASDAQ:DH) by 3.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 420,493 shares of the company’s stock after selling 15,639 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.36% of Definitive Healthcare worth $1,728,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in DH. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Definitive Healthcare during the third quarter valued at about $512,000. Hennion & Walsh Asset Management Inc. lifted its position in shares of Definitive Healthcare by 34.1% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 50,886 shares of the company’s stock valued at $209,000 after buying an additional 12,946 shares during the last quarter. Barclays PLC boosted its holdings in shares of Definitive Healthcare by 318.8% in the 3rd quarter. Barclays PLC now owns 81,916 shares of the company’s stock valued at $366,000 after buying an additional 62,354 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Definitive Healthcare by 431.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 222,090 shares of the company’s stock worth $993,000 after buying an additional 180,323 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Definitive Healthcare by 29.4% during the 3rd quarter. State Street Corp now owns 1,399,729 shares of the company’s stock worth $6,257,000 after acquiring an additional 317,952 shares in the last quarter. 98.67% of the stock is currently owned by institutional investors.

Definitive Healthcare Price Performance

Shares of NASDAQ DH opened at $2.94 on Friday. Definitive Healthcare Corp. has a 52 week low of $2.55 and a 52 week high of $8.35. The business’s 50 day moving average price is $4.09 and its 200 day moving average price is $4.26. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.33. The firm has a market cap of $331.96 million, a P/E ratio of -0.95, a P/E/G ratio of 4.06 and a beta of 1.51.

Definitive Healthcare (NASDAQ:DH) last released its quarterly earnings data on Thursday, February 27th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.04). The business had revenue of $62.29 million during the quarter, compared to analysts’ expectations of $60.60 million. Definitive Healthcare had a negative net margin of 142.38% and a positive return on equity of 1.76%. On average, sell-side analysts expect that Definitive Healthcare Corp. will post 0.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on DH shares. Barclays cut their price target on shares of Definitive Healthcare from $4.00 to $3.00 and set an “underweight” rating on the stock in a report on Monday, March 3rd. Needham & Company LLC reissued a “hold” rating on shares of Definitive Healthcare in a research report on Thursday, January 16th. Stephens assumed coverage on Definitive Healthcare in a research report on Friday, December 20th. They set an “equal weight” rating and a $5.00 target price on the stock. Finally, The Goldman Sachs Group lowered their price target on Definitive Healthcare from $4.50 to $3.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $5.35.

Definitive Healthcare Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.